

Commercial/Healthcare Exchange PA Criteria Effective: May 2004

Prior Authorization: Testosterone

<u>Products Affected</u>: Androgel, Androderm, Android, Fortesta, Methyltestosterone, Natesto, Striant, Testim, Testoderm, Testopel, Testosterone pellet, Testosterone Cream (brand name only), Vogelxo, Xyosted

Covered Uses:

- 1. Primary hypogonadism (congenital or acquired)
- 2. Hypogonadotropic hypogonadism (congenital or acquired)

Exclusion Criteria:

- 1. Sexual dysfunction, per pharmacy rider
- 2. Use in fatigue, malaise, depression and other non-specific and non-FDA approved uses

Required Medical Information:

- 1. Diagnosis
- 2. Baseline total testosterone lab result
- 3. Past medication trials

Age Restrictions: N/A

Prescriber Restrictions: N/A

Coverage Duration: 12 Months*

* Authorizations for **Testopel/Testosterone pellet** will be granted for 2 implants over 1 year. Additional implants may be approved with documented need.

Other Criteria: ConnectiCare considers Androgel to be medically necessary in males when the following criteria is met:

- 1. Patient has a lack of testosterone, due to injury, surgery, trauma, tumor, radiation to the pituitary, or bilateral cryptorchidism, torsion, or infection; confirmed by the below:
 - a. Total testosterone level <240 ng/ LH, FSH, and prolactin L (for patients with a BMI >29 a free testosterone level must also be measured) a copy of lab must be provided

OR

2. Use in treatment of male osteoporosis with objective data (BMD results) that support use, in association with hypotestosterone levels;

OR

3. Member has gender dsyphoria or undergoing gender reassignment surgery and is concomitantly receiving mental health services.

AND

4. For all other testosterone products: patient must have had an intolerance to, or treatment failure of Androgel

Last Res. December 2020



ConnectiCare.

<u>References</u>:

1. Facts and Comparisons Online

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	5/2004
2	Policy Revision	Updated Template from CCI to EH CCI P&T Review History:3/04, 6/07, 6/08, 9/09, 9/10, 4/11, 12/11, 10/12, 10/13, 10/14, 11/15, 2/16, 2/17, 5/17, 1/18 CCI Revision Record:12/08, 4/11, 5/12, 10/13, 1/14, 4/14, 6/14, 12/14, 10/15, 2/17, 5/17, 1/18, 1/19	All	4/25/2019
3	Policy Update	Removed Aveed, adopted EH Medical Policy	Products Affected	11/13/19



ConnectiCare.

4	Update	Added Testosterone pellet to products affected Added Testosterone pellet to coverage duration	Products Affected Coverage duration	12/17/2020
---	--------	--	--	------------

Last Res. December 2020



This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.